Phase 2 Motor Neurone Disease Trial, Recruiting NCT07294144 Sponsor: Washington University School of Medicine Condition: Motor Neurone Disease
Back to Motor Neurone Disease

Phase 2 Motor Neurone Disease Trial, Recruiting

NCT07294144
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older at the time of signing the consent form.
  • You have been officially diagnosed with ALS (Lou Gehrig's disease).
  • Your ALS muscle weakness began no more than 24 months (2 years) before your screening visit.
  • You have had genetic testing confirming you do not carry the SOD1 or FUS gene mutations (people with other ALS-related gene mutations may still be considered — confirm with trial site).
  • Your lung breathing capacity (measured sitting down) is at least 50% of what would be expected for someone of your sex, age, and height.
  • You are healthy enough to attend all study visits and complete all study procedures, in your doctor's opinion.
  • You are willing and able to use effective birth control during the study and for 5 months after your last dose of the study treatment.
  • If you are taking riluzole, you have been on a stable dose for at least 30 days before the study starts and plan to stay on that dose throughout.
  • If you are taking edaravone, you have been taking it for at least 60 days (2 treatment cycles) before the study starts and plan to continue throughout.
  • You are able to understand the study's purpose and risks and are willing to sign a consent form.

Who may not be able to join:

  • You have taken another experimental drug, biological treatment, or used an experimental device within the past month (or within 5 half-lives of that treatment, whichever is longer), or have ever received small interfering RNA therapy, stem cell therapy, or gene therapy.
  • You are currently enrolled in another interventional clinical trial.
  • You have had issues with drug or alcohol misuse within the past 6 months that could affect your participation, in your doctor's opinion.
  • You currently have an active infection that is not being properly treated.
  • You have an ongoing medical condition (such as severe weight loss or severe anaemia) that could interfere with the study, in your doctor's opinion.
  • You have another nerve or muscle condition that is expected to worsen during the study or affect certain test results, in your doctor's opinion.
  • You are currently pregnant or breastfeeding.
  • You have significant memory or thinking problems, dementia, psychosis, thoughts of suicide, a recent suicide attempt, or untreated severe depression within the past 90 days.
  • You have a history of allergies to a wide range of anaesthetics.
  • You have had a tracheostomy (a surgical opening in the throat for breathing).
  • You have a condition or physical factor that puts you at increased risk of uncontrolled bleeding, including bleeding disorders (such as haemophilia or Von Willebrand's disease), liver disease, or physical abnormalities near the lower spine area (confirm with trial site).
  • You need to take blood-thinning or anti-clotting medications that cannot be safely paused around the time of a spinal fluid (lumbar puncture) procedure.
  • You have an implanted device that drains fluid from around your brain or spinal cord, or an implanted catheter in your central nervous system.
  • Your blood test results show abnormalities that your doctor feels would make participation unsafe.
  • You are unable or unwilling to follow the study's requirements.
  • There are other reasons your doctor feels would make participation unsuitable.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
29 December 2025
Est. completion
1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Proportion of participants with ≥30% reduction in plasma NfL

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov